secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001493152-24-014278
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa presents NGC-Cap Phase 1b data at AACR; poster modified
----------------------------------------------------------------

- David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.
- NGC-Cap Phase 1b data shows significantly increased 5-FU exposure and improved safety vs capecitabine.
- The originally presented poster was subsequently modified; amended posters posted on company website.
- Second abstract addresses optimal dose using Phase 1 and preclinical data under Project Optimus.
- No specific numerical results disclosed in filing; detailed data available in website publications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224014278/0001493152-24-014278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224014278/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer